Heart Protection Study Trial: A Plain-English Overview of What It Established

By
Published Updated Last reviewed
Medical lab testing image for Heart Protection Study Trial: A Plain-English Overview of What It Established

At a glance

  • Trial name: Heart Protection Study (HPS)
  • N: 20,536
  • Intervention: Simvastatin 40 mg daily
  • Comparator: Matching placebo
  • Duration: Mean 5.0 years of treatment; mean 5.3 years of follow-up
  • Primary endpoint: First major vascular event (non-fatal MI, coronary death, stroke, or revascularization)
  • Key result: 24% relative risk reduction in first major vascular events (p < 0.0001)
  • Published: 2002, The Lancet

The Question HPS Set Out to Answer

By the late 1990s, statins had already proven they could prevent heart attacks in men with high cholesterol. The 4S trial (1994) showed simvastatin cut mortality in patients with prior coronary disease. WOSCOPS (1995) showed pravastatin worked for primary prevention in men with elevated LDL.

But major gaps remained. Did statins help women? Patients over 70? People with diabetes but no prior heart attack? Patients whose LDL cholesterol was already below the treatment thresholds used at the time? These were real clinical questions, and no single trial had the statistical power to answer them.

The Heart Protection Study was designed from the ground up to resolve these uncertainties. The investigators enrolled a deliberately broad population, anyone at "high enough vascular risk" to justify randomization, and powered the study to detect benefits in every major subgroup.

Who Was Enrolled

HPS recruited adults aged 40 to 80 from 69 hospitals across the United Kingdom. To qualify, a patient needed a substantial five-year risk of vascular death, defined by at least one of the following:

  • Prior coronary heart disease (CHD)
  • Prior cerebrovascular disease (stroke or TIA)
  • Peripheral arterial disease
  • Diabetes mellitus (type 1 or type 2)
  • Treated hypertension (for men aged 65 or older)

There was no minimum cholesterol requirement. This was a deliberate design choice. The investigators wanted to test whether baseline LDL mattered, or whether benefit depended only on having enough vascular risk.

The resulting cohort was unusually diverse for a cardiovascular trial of its era. Roughly 25% were women. About 28% were aged 70 or older at enrollment. Nearly 6,000 participants had diabetes. Over 3,400 had cerebrovascular disease without prior coronary events. Around 33% had a baseline LDL below 116 mg/dL (3.0 mmol/L), a level many guidelines at the time would not have flagged for treatment.

What They Were Given

After a six-week run-in on simvastatin 40 mg (to exclude patients who could not tolerate the drug or would not adhere), participants were randomized 1:1:

| Arm | Daily regimen | |-----|--------------| | Active | Simvastatin 40 mg | | Control | Matching placebo |

There was also a 2x2 factorial randomization to antioxidant vitamins (vitamin E 600 mg, vitamin C 250 mg, beta-carotene 20 mg) versus placebo. The vitamin arm showed no benefit and does not affect interpretation of the statin results.

Non-study statin use was permitted if a patient's physician felt it was indicated. By the final year, about 17% of placebo-arm patients were taking a non-study statin, while roughly 18% of simvastatin-arm patients had stopped their allocated drug. This "crossover contamination" diluted the observed treatment effect, meaning the true biological effect of simvastatin was likely larger than the 24% reduction reported.

What Was Measured

The primary endpoint was time to first major vascular event, a composite of:

  • Coronary death
  • Non-fatal myocardial infarction
  • Fatal or non-fatal stroke
  • Coronary revascularization (bypass surgery or angioplasty)

Secondary endpoints included all-cause mortality, cause-specific mortality, cancer incidence, and hospitalization. Safety monitoring covered liver enzymes, muscle symptoms, and rhabdomyolysis.

What Was Found

Lipid Changes

Simvastatin 40 mg reduced LDL cholesterol by an average of 1.0 mmol/L (roughly 39 mg/dL) compared to placebo, a relative reduction of about 29%. Total cholesterol fell by approximately 1.2 mmol/L.

Primary Outcome

Over the five-year treatment period, 19.8% of placebo patients experienced a first major vascular event compared with 14.7% of simvastatin patients.

| Outcome | Simvastatin | Placebo | Relative risk reduction | p-value | |---------|------------|---------|------------------------|---------| | Any major vascular event | 2,033 (19.8%) | 2,585 (25.2%) | 24% | <0.0001 | | Major coronary events | 898 (8.7%) | 1,212 (11.8%) | 27% | <0.0001 | | Strokes | 444 (4.3%) | 585 (5.7%) | 25% | <0.0001 | | Revascularizations | 939 (9.1%) | 1,205 (11.7%) | 24% | <0.0001 |

All-cause mortality fell from 14.7% to 12.9%, a 13% relative reduction (p = 0.0003), driven by the drop in vascular deaths.

The Subgroup Results That Changed Practice

This is where HPS distinguished itself from every prior statin trial. The 24% risk reduction held up across subgroups that had never been adequately tested:

| Subgroup | Events (simvastatin vs. placebo) | Relative reduction | |----------|--------------------------------|-------------------| | Women (n = 5,082) | Consistent benefit | ~24% | | Age 70-80 (n = 5,806) | Consistent benefit | ~24% | | Diabetes, no prior CHD (n = 3,982) | 505 vs. 601 | ~22% | | Baseline LDL <116 mg/dL (n = 6,793) | Consistent benefit | ~24% | | Prior stroke, no CHD (n = 3,280) | Consistent benefit | ~25% |

The finding in patients with low baseline LDL was arguably the most consequential. It demonstrated that the relative benefit of LDL lowering was independent of the starting point, a principle that the 2018 ACC/AHA cholesterol guidelines later incorporated by shifting away from rigid LDL targets toward risk-based treatment decisions.

Safety

Simvastatin 40 mg showed a clean safety profile across five years:

  • Myopathy (CK > 10x ULN with symptoms): 11 cases in the simvastatin group vs. 6 in placebo. No excess rhabdomyolysis cases.
  • Liver transaminases (> 4x ULN): No significant difference between groups.
  • Cancer: No increase in any cancer type. This was an important reassurance given theoretical concerns about cholesterol-lowering and cancer risk.
  • Hemorrhagic stroke: No increase, despite the overall stroke reduction.

The FDA prescribing information for simvastatin continues to reference HPS safety data as part of the risk-benefit evidence.

What the Trial Did Not Show

Honest interpretation requires noting several limitations the investigators themselves acknowledged.

No dose comparison. Every participant received 40 mg. The trial cannot tell us whether 20 mg would have been enough or 80 mg would have been better. Subsequent data, particularly from the SEARCH trial (2010), showed that 80 mg simvastatin increased myopathy risk without proportional benefit, leading the FDA to restrict the 80 mg dose in 2011.

Run-in bias. The six-week run-in excluded patients who stopped the drug early or had side effects. This means HPS enrolled a "tolerator-enriched" population. Real-world discontinuation rates are higher than what the trial observed.

Crossover contamination. As noted, 17% of placebo patients eventually took a statin. The true efficacy of simvastatin 40 mg in a world where the alternative is genuinely no statin is probably larger than 24%.

Limited ethnic diversity. HPS was overwhelmingly a white British cohort. Later trials, including MEGA (Japanese population) and others, confirmed statin benefits across ethnicities, but HPS alone cannot speak to this.

No head-to-head with other statins. Simvastatin 40 mg is a moderate-intensity statin by current classification. Whether high-intensity alternatives like atorvastatin 80 mg would have produced even greater benefit in this population was addressed by subsequent trials like TNT and PROVE-IT.

What HPS Means for Practice Today

HPS did not invent statin therapy. What it did was remove the guardrails. Before HPS, clinicians debated whether to offer statins to women, to older adults, to diabetic patients without heart disease, or to anyone with "normal" cholesterol. After HPS, the answer was consistently yes, if the patient's overall vascular risk was high enough.

Current ACC/AHA guidelines reflect this directly. The four statin-benefit groups, which include diabetic patients aged 40 to 75 and patients with clinical atherosclerotic cardiovascular disease regardless of LDL, trace their evidence base substantially to HPS.

The trial also cemented a conceptual shift. Rather than treating a lab number (LDL cholesterol), clinicians now treat a risk profile. The "lower is better" principle, extended by later trials with ezetimibe and PCSK9 inhibitors, started gaining traction because HPS showed benefit even when LDL was already low.

Simvastatin 40 mg itself has been partially superseded. Atorvastatin and rosuvastatin achieve greater LDL reductions at comparable or lower myopathy risk and dominate current prescribing. But the clinical evidence from HPS remains foundational. The questions it answered, about who benefits from statin therapy, have not needed to be re-asked.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. The Lancet. 2002;360(9326):7-22. PubMed
  2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet. 1994;344(8934):1383-1389. PubMed
  3. SEARCH Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction. The Lancet. 2010;376(9753):1658-1669. PubMed
  4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. PubMed
  5. FDA. Simvastatin (Zocor) prescribing information. FDA Label